UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
PloS one, 2018, Volume 13, Issue 10, p. e0205134
Journal Article
U.S. pharmacist, ISSN 0148-4818, 10/2011, Volume 36, Issue 10, pp. 60 - 68
Journal Article
Zeitschrift für Rheumatologie, ISSN 0340-1855, 07/2009, Volume 68, Issue 5, p. 380
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 07/2017, Volume 77, Issue 11, pp. 1221 - 1233
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Abatacept - pharmacology | Antirheumatic Agents - administration & dosage | Humans | Treatment Outcome | Clinical Trials as Topic | Methotrexate - therapeutic use | Methotrexate - adverse effects | Abatacept - adverse effects | Immunoconjugates - pharmacology | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Immunoconjugates - therapeutic use | Adult | Antirheumatic Agents - pharmacokinetics | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Intravenous administration | Pathogenesis | Clinical trials | Systematic review | Lymphocytes T | Arthritis | Proteins | Cell activation | Lymphocytes | Remission | Methotrexate | Fusion protein | Antigens | Signs and symptoms | Biological products | Rheumatology | T cell receptors | Patients | Immunogenicity | Tumor necrosis factor | Rheumatoid arthritis | Structural damage | TNF inhibitors | Cost analysis | Health risk assessment
Journal Article
Expert opinion on investigational drugs, ISSN 1354-3784, 04/2016, Volume 25, Issue 4, pp. 493 - 499
treatment | lupus nephritis | Systemic lupus erythematosus | abatacept | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Abatacept - pharmacology | Abatacept - adverse effects | Immunologic Factors - chemistry | Animals | Abatacept - therapeutic use | Humans | Lupus Erythematosus, Systemic - drug therapy | Abatacept - chemistry | Lupus Erythematosus, Systemic - metabolism | Immunologic Factors - adverse effects | Immunologic Factors - pharmacology | Immunologic Factors - therapeutic use | Index Medicus
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 02/2017, Volume 76, Issue 2, pp. 386 - 391
Rheumatoid Arthritis | Anti-TNF | Epidemiology | Life Sciences & Biomedicine | Rheumatology | Science & Technology | Melanoma - epidemiology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Risk Factors | Europe - epidemiology | Male | Skin Neoplasms - epidemiology | Incidence | Rituximab - therapeutic use | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Aged, 80 and over | Adult | Female | Registries | Aged | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Complications and side effects | Usage | Biological products | Tumor necrosis factor inhibitors | Rheumatoid arthritis | Risk factors | Skin cancer | Index Medicus | Clinical and Epidemiological Research | 1506 | Medicin och hälsovetenskap
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 333 - 343
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Kidney Failure, Chronic - mortality | Single-Blind Method | Glomerular Filtration Rate | Kidney Failure, Chronic - surgery | Follow-Up Studies | Humans | Kaplan-Meier Estimate | Graft Survival | Abatacept - administration & dosage | Cyclosporine - therapeutic use | Abatacept - adverse effects | Cyclosporine - adverse effects | Intention to Treat Analysis | Immunosuppressive Agents - adverse effects | Kidney Transplantation - mortality | Immunosuppressive Agents - administration & dosage | Treatment outcome | Usage | Safety and security measures | Kidneys | Analysis | Organ transplant recipients | Belatacept | Dosage and administration | Transplantation | Health aspects | Immunosuppression | Renal function | Epidermal growth factor receptors | Transplants & implants | Cyclosporins | Immunotherapy | Survival | Patients | Clinical outcomes | Glomerular filtration rate | Kidney transplantation | Index Medicus | Abridged Index Medicus
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 12/2017, Volume 23, Issue 12, pp. 2048 - 2056
Rejection | Stem cell transplantation | Abatacept | CD34 | T cell | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Abatacept - pharmacology | Antigens, CD34 | Reoperation | CD3 Complex | Graft Rejection - prevention & control | Humans | Graft Rejection - etiology | T-Lymphocytes - transplantation | Abatacept - administration & dosage | Animals | Heterografts | Time Factors | Abatacept - therapeutic use | Mice, Inbred NOD | T-Lymphocytes - immunology | Index Medicus
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 04/2019, Volume 78, Issue 4, pp. 456 - 464
tumor necrosis factor inhibitor | tocilizumab | biologic therapy | serious infections | abatacept | bacterial infections | rheumatoid arthritis | Life Sciences & Biomedicine | Rheumatology | Science & Technology | Risk Assessment - methods | United States - epidemiology | Virus Diseases - epidemiology | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Opportunistic Infections - chemically induced | Arthritis, Rheumatoid - drug therapy | Bacterial Infections - chemically induced | Antirheumatic Agents - adverse effects | Adult | Biological Products - adverse effects | Female | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Databases, Factual | Antibodies, Monoclonal, Humanized - adverse effects | Virus Diseases - chemically induced | Antibodies, Monoclonal, Humanized - therapeutic use | Opportunistic Infections - epidemiology | Comorbidity | Arthritis, Rheumatoid - epidemiology | Tumor Necrosis Factor Inhibitors - adverse effects | Abatacept - adverse effects | Abatacept - therapeutic use | Bacterial Infections - epidemiology | Aged | Cohort Studies | Studies | Bacterial infections | Tumor necrosis factor | Rheumatoid arthritis | Opportunist infection | Respiratory tract diseases | Tumor necrosis factor-TNF | Bacteria | Skin | Health risk assessment | Bacteremia | Tumors | Index Medicus
Journal Article
Immunity (Cambridge, Mass.), ISSN 1074-7613, 05/2016, Volume 44, Issue 5, pp. 973 - 988
Life Sciences & Biomedicine | Immunology | Science & Technology | Immunotherapy - methods | Receptor Cross-Talk | Receptors, Antigen, T-Cell - metabolism | Signal Transduction | Lymphocyte Activation | Humans | Autoimmune Diseases - immunology | Homeostasis | CD28 Antigens - immunology | Molecular Targeted Therapy | CD28 Antigens - metabolism | Autoimmune Diseases - genetics | Animals | CD28 Antigens - genetics | Abatacept - therapeutic use | Immunotherapy - trends | Autoimmune Diseases - therapy | T-Lymphocytes - immunology | Mice | CTLA-4 Antigen - antagonists & inhibitors | Epigenetic inheritance | Therapeutics | Family | Drug discovery | T cells | Homeopathy | Materia medica and therapeutics | Antigens | Phosphorylation | Disease | Cytokines | Lymphocytes | Rheumatoid arthritis | Mortality | Clinical trials | Ligands | T cell receptors | Laboratory animals | Gene expression | Index Medicus
Journal Article